Ventripoint Seeks China Approval for VMS+ 4.0, Showcases at AEPC Congress
Ventripoint submitted its VMS+ 4.0 echocardiography AI platform to China’s NMPA via an expedited green channel on April 28, targeting 330 million cardiovascular patients. The company also plans to showcase VMS+ at the AEPC congress in Padua (May 12–16) following new commercial agreements in California and First Nations communities.
1. NMPA Submission for VMS+ 4.0
On April 28, Ventripoint’s strategic partner Lishman Global submitted the VMS+ 4.0 system to China’s National Medical Products Administration via the expedited green channel pathway, positioning the company to serve an estimated 330 million cardiovascular disease patients with MRI-equivalent volumetric measurements on existing ultrasound platforms.
2. AEPC Exhibition in Padua
Ventripoint plans to exhibit its VMS+ 4.0 platform at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, Italy (May 12–16), emphasizing streamlined cardiac workflow and longitudinal ventricular assessments for congenital heart disease.
3. Commercial Partnerships and Validation Events
Since early 2026, Ventripoint has stacked industry validations, earning an Edison Award, signing a deployment agreement with LG Consulting Solutions for Northern California hospitals, and partnering to deliver AI 3D heart mapping in Indigenous community settings, reinforcing its regulatory, commercial and clinical momentum.